Nuvectis Pharma, Inc.
NASDAQNVCT short interest falls 26.7% over one week to 5.1% of float, though cost to borrow remains low at 2.98%.
Nuvectis Pharma heads into its August 6 earnings print with an unusually constructive insider-buying signal sitting against a backdrop of persistent short pressure and a stock that has pulled back sharply from recent…
Why this matters: Five days ago, NVCT had zero shares left to borrow. Now availability has recovered to 40% — but short sellers haven't retreated. They've added more positions, cost to borrow has surged 83%, and the…
Snapshot as of 15 Aug 2026
Every share in NVCT's lending pool is now deployed. Availability has collapsed to 0% — the tightest the borrow market has been in the stock's recorded history — as a 97% weekly rally drew a wave of new short positions…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NVCT — free to start on ORTEX.
Sign up for free →Open NVCT on ORTEX